Abstract
OBJECTIVE: This study aimed to develop and evaluate a nomogram for predicting preterm birth in patients with intrahepatic cholestasis of pregnancy (ICP), with a view to assisting clinical management and intervention. METHODS: This retrospective observational study included 257 pregnant women with ICP from Sichuan Provincial People's Hospital between January 1, 2022 and July 30, 2024. The routine clinical and laboratory information of these patients were also collected. We used the least absolute shrinkage and selection operator (LASSO) and multivariable logistic regression analysis to investigate the association between clinical and laboratory data and preterm birth in ICP patients. A nomogram was developed to predict the likelihood of preterm birth in ICP patients. The prediction accuracy of the model was evaluated by consistency index (C-index), receiver operating characteristic (ROC) curve, area under the curve (AUC), and calibration curve. Decision curve analysis (DCA) was used to evaluate its applicability in clinical practice. RESULTS: Among the 257 ICP patients, 56 (21.79%) were diagnosed with preterm birth. Cases were randomly divided into a training set (154 cases) and a test set (103 cases). A nomogram was developed to predict preterm birth in ICP patients based on height, twin pregnancy (TP), gestational age at diagnosis (GA at diagnosis), and total bile acid level (TBA) at diagnosis. The calibration curve of the training set was close to the diagonal (C-index = 0.864), and the calibration curve of the test set was also close to the diagonal (C-index = 0.835). These results indicate that the model has a good consistency. The AUC of the training group and the test group were 0.864 and 0.836, respectively, indicating the good accuracy of the model. The DCA reveals that this nomogram could be applied to clinical practice. CONCLUSION: The combination of TBA level, TP, height and GA at diagnosis is an effective model for identifying preterm birth in ICP patients. These results will help guide the clinical management and treatment of patients with ICP, thereby reducing maternal and infant safety issues caused by preterm birth.